ASCO Update Call June 6, 2021 © 2021, Iovance Biotherapeutics, Inc 1 | --- | --- | |---------------------------------------------------------------------------------------------------------------------------|-------------------------| | Agenda | | | | | | • Corporate Update : Fred Vogt, incoming Interim CEO and President • ASCO Updates for Lifileucel in Advanced Melanoma | : Omid Hamid, MD, Chief | | of Research/Immuno-Oncology, The Angeles Clinic & Research Institute | | | • Financial Summary : Jean-Marc B ...

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q1 2021 Earnings Conference Call May 6, 2021 4:30 PM ET Company Participants Maria Fardis - Chief Executive Officer & President Friedrich Finckenstein - Chief Medical Officer Jean Marc Bellemin - Chief Financial Officer Sara Pellegrino - Vice President, Investor and Public Relations Jim Ziegler - Senior Vice President, Commercial Conference Call Participants Michael Yee - Jefferies LLC Peter Lawson - Barclays Bank Mark Breidenbach - Oppenheimer Boris Peaker - Cowe ...

Table of Contents U. S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-36860 IOVANCE BIOTHERAPEUTICS, INC. (Exact name of issuer as specified in its charter) Delaware 75-3254381 (State or other jurisdict ...

| --- | --- | --- | |-------|-------|-------| | | | | | | | | | | | | | --- | --- ...

| --- | --- | --- | |-------|-------|-------| | | | | | | | | | | | | | --- | --- ...

| --- | --- | --- | --- | --- | |---------------------------------------------------------------------------|--------------------------------------|-------|---------------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Tumor Infiltrating Lymphocyte Cell Therapy for Treatment of Solid Tumors | | | February 2021 | | | | © 2021, Iovance Biotherapeutics, Inc | | | 1 | | --- ...

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q4 2020 Earnings Conference Call February 25, 2021 4:30 PM ET Company Participants Maria Fardis - Chief Executive Officer & President Friedrich Finckenstein - Chief Medical Officer Jean Marc Bellemin - Chief Financial Officer Sara Pellegrino - Vice President, Investor and Public Relations Conference Call Participants Mark Breidenbach - Oppenheimer Peter Lawson - Barclays Bank Biren Amin - Jefferies Reni Benjamin - JMP Securities Mara Goldstein - Mizuho Securities ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transaction period from __________ to __________ Commission file number: 001-36860 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Its Charter) Del ...

| --- | --- | --- | --- | --- | |-------------------------------------------------------------------------------------|---------------------------------|-------|---------------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Investigating the Power of Tumor Infiltrating Lymphocytes for Treatment of Cancer | | | November 2020 | | | | © 2020, Iovance Biotherapeutics | | | | ongoing clinical trials and anticipated clinical trials for our current product candidates (including both Company ...

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q3 2020 Earnings Conference Call November 5, 2020 4:30 PM ET Company Participants Sara Pellegrino - VP, IR & Public Relations Maria Fardis - CEO, President & Director Friedrich Finckenstein - Chief Medical Officer Michael Swartzburg - VP, Finance and Interim Principal Financial Officer & Principal Accounting Officer Conference Call Participants Peter Lawson - Barclays Bank Mara Goldstein - Mizuho Securities Mark Breidenbach - Oppenheimer Boris Peaker - Cowen and C ...